2023
Factors associated with clinical trial participation for patients with renal cell carcinoma
Shinder B, Kim S, Srivastava A, Patel H, Jang T, Mayer T, Saraiya B, Ghodoussipour S, Singer E. Factors associated with clinical trial participation for patients with renal cell carcinoma. Urologic Oncology Seminars And Original Investigations 2023, 41: 208.e1-208.e8. PMID: 36868881, PMCID: PMC10106382, DOI: 10.1016/j.urolonc.2023.01.022.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCell carcinomaClinical trial participationClinical trialsOverall survivalClinical stageTrial patientsTrial participantsCharlson-Deyo comorbidity scoreAssociated with trial participationCompare overall survivalNational Cancer DatabaseLog-rank testClinical trial patientsPatient sociodemographic factorsAssociated with clinical trial participationMedian OSSuperior OSCancer DatabaseOncology clinical trialsSurvival outcomesMale patientsCase-control designPatient cohortControl cohort
2022
Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma
Patel HV, Kim S, Srivastava A, Shinder BM, Sterling J, Saraiya B, Mayer TM, Ghodoussipour S, Jang TL, Singer EA. Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 20: 296-296.e9. PMID: 35105510, PMCID: PMC9149103, DOI: 10.1016/j.clgc.2022.01.001.Peer-Reviewed Original ResearchConceptsStage IV RCCMetastatic renal cell carcinomaNational Cancer DatabasePalliative interventionsRenal cell carcinomaMetastatic RCCClinical factorsCell carcinomaMultivariable logistic regression modelComprehensive cancer programsQuality of lifeLogistic regression modelsSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusOncologic careInsurance statusCancer DatabaseCancer programsEarly initiationIntervention utilizationTreatment-specific mannerPatientsPI use
2020
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond
Srivastava A, Patel HV, Kim S, Shinder B, Sterling J, Tabakin AL, Polotti CF, Saraiya B, Mayer T, Kim IY, Ghodoussipour S, Patel HD, Jang TL, Singer EA. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urologic Oncology Seminars And Original Investigations 2020, 39: 247-257. PMID: 33223368, PMCID: PMC7574787, DOI: 10.1016/j.urolonc.2020.10.012.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaUpstaging riskOverall survivalCell carcinomaNonclear cell renal cell carcinomaOrgan-confined renal cell carcinomaCox proportional hazards modelNational Cancer DatabaseCell renal cell carcinomaKaplan-Meier curvesProportional hazards modelSmall renal massesCOVID-19Logistic regression modelsPT3a upstagingDelaying surgeryPrimary endpointSecondary endpointsPatient comorbiditiesMeier curvesElective surgeryRadical nephrectomyTumor histologyClinical stageRCC patientsUrologic oncology surgery during COVID-19: a rapid review of current triage guidance documents
Shinder BM, Patel HV, Sterling J, Tabakin AL, Kim IY, Jang TL, Singer EA. Urologic oncology surgery during COVID-19: a rapid review of current triage guidance documents. Urologic Oncology Seminars And Original Investigations 2020, 38: 609-614. PMID: 32507546, PMCID: PMC7260595, DOI: 10.1016/j.urolonc.2020.05.017.Peer-Reviewed Original ResearchChallenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery.
Patel H, Shinder B, Srinivasan R, Singer E. Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. Current Opinion In Oncology 2020, 32: 240-249. PMID: 32195679, PMCID: PMC9788417, DOI: 10.1097/cco.0000000000000621.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellChemotherapy, AdjuvantClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCytoreduction Surgical ProceduresHumansKidney NeoplasmsNeoadjuvant TherapyNeoplasm MetastasisProtein Kinase InhibitorsRandomized Controlled Trials as TopicConceptsMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaBiology of metastatic renal cell carcinomaTreatment of metastatic renal cell carcinomaManagement of metastatic renal cell carcinomaTyrosine kinase inhibitor cabozantinibProgrammed cell death protein 1 antibodyIntroduction of novel therapiesCombination of axitinibFirst-line therapyUS Food and Drug AdministrationFood and Drug AdministrationCytoreductive surgeryAdvanced RCCSystemic therapyCombination therapySurvival benefitTargeted therapyPatient selectionTreatment paradigmNovel therapiesTherapeutic advancesCombinatorial therapyTreatment advances
2019
Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014
Tabakin AL, Shinder BM, Kim S, Rivera-Nunez Z, Polotti CF, Modi PK, Sterling JA, Farber NJ, Radadia KD, Parikh RR, Kim IY, Saraiya B, Mayer TM, Singer EA, Jang TL. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clinical Genitourinary Cancer 2019, 18: e194-e201. PMID: 31818649, DOI: 10.1016/j.clgc.2019.10.018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultFollow-Up StudiesHumansKaplan-Meier EstimateLymph Node ExcisionLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrchiectomyRegistriesRetroperitoneal SpaceRetrospective StudiesSeminomaSurvival RateTesticular NeoplasmsTestisTreatment OutcomeUnited StatesYoung AdultConceptsRetroperitoneal lymph node dissectionPrimary retroperitoneal lymph node dissectionLymph node dissectionOverall survivalTesticular seminomaNode dissectionRole of RPLNDTesticular nonseminomatous germ cell tumorsNational Cancer Data BaseNonseminomatous germ cell tumorsPrimary testicular cancerFive-year OSFirst-line treatmentKaplan-Meier methodOngoing prospective trialsGerm cell tumorsIIB diseaseOS ratesPrimary chemotherapyPrimary therapyProspective trialFinal cohortStage IIATumor histologyClinical stageA Case Study Evaluating the Diagnosis and Treatment of a Rare Mesenchymal Tumor
Shinder B, Sack J, Sadimin E, Tunuguntla H. A Case Study Evaluating the Diagnosis and Treatment of a Rare Mesenchymal Tumor. Urology 2019, 131: e1-e2. PMID: 31247212, DOI: 10.1016/j.urology.2019.06.019.Peer-Reviewed Case Reports and Technical NotesConceptsCellular angiofibromaPainless right inguinal massRare mesenchymal tumorRight inguinal massBenign mesenchymal neoplasmLimited treatment optionsOval-shaped massSurgical excisionInguinal massMesenchymal tumorsMesenchymal neoplasmsCT scanTreatment optionsSpermatic cordImmunohistochemical analysisRadiographic featuresImaging modalitiesAngiofibromaDiagnostic casesCD34NeoplasmsTumorExcisionDesminCord
2018
Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database
Farber NJ, Rivera-Núñez Z, Kim S, Shinder B, Radadia K, Sterling J, Modi PK, Goyal S, Parikh R, Mayer TM, Weiss RE, Kim IY, Elsamra SE, Jang TL, Singer EA. Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database. Urologic Oncology Seminars And Original Investigations 2018, 37: 26-32. PMID: 30446458, PMCID: PMC6295174, DOI: 10.1016/j.urolonc.2018.10.004.Peer-Reviewed Original ResearchConceptsLymph node dissectionNonmetastatic renal cell carcinomaRenal cell carcinomaMedian overall survivalNational Cancer DatabaseOverall survivalCell carcinomaCancer DatabasePropensity score-weighted analysisLow-stage diseaseLN-positive patientsLymph node involvementCox regression analysisSubgroup of patientsT stages 1Contemporary practice patternsRegression analysisChi-square testOS benefitPotential overutilizationNode dissectionUnderwent surgeryNode involvementPatient demographicsPositive patients
2017
Management of Postradical Prostatectomy Urinary Incontinence: A Review
Radadia K, Farber N, Shinder B, Polotti C, Milas L, Tunuguntla H. Management of Postradical Prostatectomy Urinary Incontinence: A Review. Urology 2017, 113: 13-19. PMID: 29031841, DOI: 10.1016/j.urology.2017.09.025.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPelvic floor muscle trainingTransurethral bulking agentsArtificial urinary sphincterTreat overactive bladderPostprostatectomy urinary incontinenceQuality of life of patientsDetrusor hypocontractilityMale slingRadical prostatectomyStress incontinenceOveractive bladderSphincter incompetenceUrinary sphincterOverflow incontinenceUrinary incontinenceTreatment modalitiesLife of patientsEfficacious optionMuscle trainingIncontinenceSuccess ratePatientsTreatmentBulking agentsProstatectomyBowel preparation prior to reconstructive urologic surgery in pediatric myelomeningocele patients.
Farber N, Davis R, Grimsby G, Shinder B, Cannon G, Jacobs M, Ost M, Schneck F, Stephany H, Gargollo P, Dwyer M. Bowel preparation prior to reconstructive urologic surgery in pediatric myelomeningocele patients. Canadian Journal Of Urology 2017, 24: 9038-9042. PMID: 28971794.Peer-Reviewed Original ResearchConceptsMechanical bowel preparationReconstructive urologic surgeryBowel preparationUrological surgeryPostoperative complicationsPerioperative measuresStatistically significant differencePostoperative outcomesPediatric patientsMyelomeningocele patientsSignificant differencePreoperative mechanical bowel preparationPreoperative bowel preparationStandard of careAugmentation cystoplastyComplication rateUrinary diversionNo significant differenceRandomized studyPatient populationOperative timeSurgeryComplicationsPatientsMyelomeningoceleRisk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study
Kim DK, Parihar JS, Kwon YS, Kim S, Shinder B, Lee N, Farber N, Ahlering T, Skarecky D, Yuh B, Ruel N, Kim WJ, Rha KH, Kim IY. Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study. Asian Journal Of Andrology 2017, 20: 9-14. PMID: 28440262, PMCID: PMC5753561, DOI: 10.4103/1008-682x.196852.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerCytoreductive prostatectomyUrinary incontinenceProstate cancerBlood lossRadical prostatectomyCare androgen-deprivation therapyBenefit of cytoreductionUrinary incontinence rateAndrogen deprivation therapyMulti-institutional clinical trialsIncidence of complicationsMajor complication rateOnly independent predictorLonger operative timeRisk of complicationsTertiary surgical centerMulti-institutional studyDeprivation therapyBony metastasesIncontinence ratesPerioperative complicationsComplication rateCRP groupIndependent predictors
2016
Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab
Shinder B, Farber N, Mayer T, Singer E. Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab. Clinical Genitourinary Cancer 2016, 15: e165-e167. PMID: 27396730, PMCID: PMC5083235, DOI: 10.1016/j.clgc.2016.04.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements